EDGAR Filing Documents for 0001558370-20-000322

Form 8-K - Current report:

SEC Accession No. 0001558370-20-000322

Filing Date

2020-01-29

Accepted

2020-01-29 16:33:01

Documents

Period of Report

2020-01-28

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	f8-k.htm	8-K	90403
2	EX-2.1	ex-2d1.htm	EX-2.1	895105
3	EX-4.1	ex-4d1.htm	EX-4.1	162414
4	EX-10.1	ex-10d1.htm	EX-10.1	322945
5	EX-10.2	ex-10d2.htm	EX-10.2	51645
6	EX-10.3	ex-10d3.htm	EX-10.3	52053
7	EX-10.4	ex-10d4.htm	EX-10.4	90160
8	EX-99.1	ex-99d1.htm	EX-99.1	41082
9	GRAPHIC	ex-2d1g001.jpg	GRAPHIC	2290
	Complete submission text file	0001558370-20-000322.txt		1710497

Mailing Address 115 NICHOLSON LANE SAN JOSE CA 95134

Business Address 115 NICHOLSON LANE SAN JOSE CA 95134 650-889-5020

BioPharmX Corp (Filer) CIK: 0001504167 (see all company filings)